Pages that link to "Q30925583"
Jump to navigation
Jump to search
The following pages link to Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data (Q30925583):
Displaying 50 items.
- Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard (Q21093288) (← links)
- Epidemiology and reporting characteristics of systematic reviews (Q21144675) (← links)
- Reporting bias in medical research - a narrative review (Q21203744) (← links)
- The impact of prescribed psychotropics on youth (Q21203787) (← links)
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Q21562278) (← links)
- Early interventions to prevent psychosis: systematic review and meta-analysis (Q22242061) (← links)
- Efficacy of antidepressants in juvenile depression: meta-analysis (Q22255557) (← links)
- Statistical issues in first-in-man studies (Q23018507) (← links)
- Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Q24187748) (← links)
- Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews (Q24198890) (← links)
- Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews (Q24200620) (← links)
- Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews (Q24202052) (← links)
- Overview of the safety of regular formoterol or salmeterol in children with asthma (Q24202543) (← links)
- Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents (Q24202831) (← links)
- Newer generation antidepressants for depressive disorders in children and adolescents (Q24202873) (← links)
- Sertraline versus other antidepressive agents for depression (Q24235928) (← links)
- Sertraline versus other antidepressive agents for depression (Q24241023) (← links)
- Sertraline versus other antidepressive agents for depression (Q24241157) (← links)
- Interventions for mood and anxiety disorders, and self harm in young offenders (Q24241950) (← links)
- Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents (Q24244127) (← links)
- Psychotherapy for depression in children and adolescents (Q24246387) (← links)
- Publication bias: what are the challenges and can they be overcome? (Q24282598) (← links)
- Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials (Q24556639) (← links)
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review (Q24556640) (← links)
- CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials (Q24614627) (← links)
- Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials (Q24632255) (← links)
- Pharmacotherapy of aggression in children and adolescents: efficacy and effect size (Q24648097) (← links)
- Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials (Q24648108) (← links)
- The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? (Q24650519) (← links)
- Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial (Q24669688) (← links)
- Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study (Q24678875) (← links)
- Psychometric properties and clinical utility of the Scale for Suicidal Ideation (SSI) in adolescents (Q24793146) (← links)
- Is it ethical to use enhancement technologies to make us better than well? (Q24809605) (← links)
- Suicide attempts in clinical trials with paroxetine randomised against placebo (Q24810695) (← links)
- Clinical trial registration: the differing views of industry, the WHO, and the Ottawa Group (Q24812113) (← links)
- Perspectives on the efficacy of antidepressants for child and adolescent depression (Q24812722) (← links)
- Research ethics committees: agents of research policy? (Q24815381) (← links)
- Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports (Q26773320) (← links)
- Do the CONSORT and STRICTA Checklists Improve the Reporting Quality of Acupuncture and Moxibustion Randomized Controlled Trials Published in Chinese Journals? A Systematic Review and Analysis of Trends (Q26774822) (← links)
- Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis (Q26782153) (← links)
- Inadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic review (Q26995526) (← links)
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Q27860868) (← links)
- The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm (Q28066714) (← links)
- Using journal impact factors to correct for the publication bias of medical studies (Q28200504) (← links)
- Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta-analysis (Q28262885) (← links)
- Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? (Q28279067) (← links)
- Quality and quantity of information in summary basis of decision documents issued by health Canada (Q28541228) (← links)
- Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review (Q28554247) (← links)
- Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis (Q28650054) (← links)
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials (Q28710019) (← links)